DANIEL BEQUILLARD: Open Payments
NPI 1154410041 · PORT ARANSAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,334 in 60 payments from 16 companies in 2025. Trend: 2023 $1,188 · 2024 $919 · 2025 $1,334
Food & beverage: $1,334
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $296 |
| Amgen Inc. | 16 | $289 |
| AstraZeneca Pharmaceuticals LP | 8 | $201 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $104 |
| GlaxoSmithKline, LLC. | 4 | $99 |
| Novo Nordisk Inc | 3 | $71 |
| ABBVIE INC. | 3 | $65 |
| Lilly USA, LLC | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
Products named: Kerendia, REPATHA, AIRSUPRA, OTEZLA, CAPLYTA, TRELEGY ELLIPTA, Ozempic, QULIPTA.
Industry payments across TX — which companies pay providers there.
